Indehaveren af markedsføringstilladelsen indvilligede i at slette indikationen for overfladisk blærecancer, og CHMP foreslog derfor følgende reviderede ordlyd:
The MAH agreed to delete the indication in superficial bladder cancer and the CHMP accordingly proposed the following revised wording: